BC Platforms, a world leader in genomic data management and analytics, today announced that it has formed a collaboration with Debiopharm, a Swiss pharmaceutical company, to deliver a complete clinical and genomic data management solution to support its innovative oncology pipeline, including investigational product programs for Debio 0123 (Selective WEE1 inhibitor), diagnostic molecular screening for Debio 1347 (FGFR inhibitor) and clinical exploratory results for Debio 1143 (IAP inhibitor). Debiopharm’s business development initiatives include data from all molecule type proteins, peptides, small molecules.
BC Platforms’ solution will enable Debiopharm to carry out the consolidation and harmonisation of data, both within Debiopharm internally and also in the future with external clinical research organizations. The goal of the collaboration is to make use of previously untapped data that may hold interesting findings, especially when combined and harmonized. In doing so, the company expects to provide greater insights into Debiopharm’s development pipeline in order to support specific therapeutic strategies and add value to potential partnering discussions.
BC Platforms technology will enable Debiopharm to browse through vast amounts of anonymous clinical research data and to automize previously manual tasks, increasing the data output value to ultimately provide benefits to patients. BC Platforms will also deliver novel software solutions for clinical and multi-omics data research including its data visualisation dashboard, ontology browser and auto-curator.
René van den Bersselaar, CIO at Debiopharm International commented on the partnership, “We are very confident in BC Platforms’ ability to manage and integrate vast amounts of clinical and genomic data in a manner that will provide valuable insights to support our development programs, particular in the area of oncology. This program is essential in our company when it comes to developing and managing data for our new transformational therapeutic assets.”
Tero Silvola, CEO of BC Platforms, said, “We are delighted to be supporting Debiopharm with the management of their clinical and genomic research data. Debiopharm has been extremely visionary in its approach to digital health in research and data management and we look forward to supporting them in building additional value for their customers and patients.”
Debiopharm Innovation Fund was a lead investor in BC Platforms $10 million series B financing in May 2017.
Debiopharm develops innovative therapies that target high unmet medical needs in oncology and bacterial infections. Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds and technologies for in-licensing, clinically demonstrate their safety and efficacy and then select large pharmaceutical commercialization partners to maximize patient access globally. Visit us www.debiopharm.com.
Follow us @DebiopharmNews at http://twitter.com/DebiopharmNews